Partners in the Target ALS Community
Academic Institutions
Universities and research institutes are driving new ideas and identifying new targets for ALS. Target ALS is proud to partner with the following institutions:
- Barrow Neurological Institute, Phoenix, AZ
- Baylor College of Medicine, Houston, TX
- Boston Children’s Hospital, Boston, MA
- Brandeis University, Waltham, MA
- Cedars–Sinai Medical Center, Los Angeles, CA
- Columbia University, New York City, NY
- Georgetown University, Washington, DC
- Gladstone Institutes, San Francisco, CA
- Harvard University, Cambridge, MA
- Hôpital de la Pitié Salpétrière, Paris, France
- INSERM, Paris, France
- Johns Hopkins University, Baltimore, MD
- Ludwig Institute for Cancer Research, San Diego, CA
- Massachusetts General Hospital, Boston, MA
- Mayo Clinic, Jacksonville, FL
- Mayo Clinic, Rochester, MN
- National Institute of Environmental Health, Research Triangle Park, NC
- Northwestern University, Chicago, IL
- Salk Institute for Biological Studies, La Jolla, CA
- St. Jude Children’s Hospital, Memphis, TN
- Stanford University, Stanford, CA
- The Scripps Research Institute, Jupiter, FL
- The Weizmann Institute of Science, Rehovot, Israel
- Thomas Jefferson University, Philadelphia, PA
- Ulster University, Belfast, UK
- University of California, San Diego, CA
- University of California, San Francisco, CA
- University of Chicago, Chicago, IL
- University of Florida Gainesville, FL
- University of Massachusetts, Worcester, MA
- University of Miami, Coral Gables, FL
- University of Michigan, Ann Arbor, MI
- University of North Carolina, Chapel Hill, NC
- University of Oxford, Oxford, UK
- University of Paris-Descartes, Paris, France
- University Pennsylvania, Philadelphia, PA
- University of Zurich, Zurich, Switzerland
- Washington University, St. Louis, MO
- University of Utah, Salt Lake City, UT
Pharma/Biotech Partners
Representatives from the biomedical industry are collaborating within research consortia, serving as members of the Independent Review Committee, serving on our Board, participating in our Annual Meeting, and engaging with us at all levels of strategic initiatives. We are grateful to the following:
- AbbVie, North Chicago, IL
- Aclipse Therapeutics, Radnor, PA
- AcuraStem Inc., Monrovia, CA
- AC Immune, Lausanne, Switzerland
- ADRx, Inc., Westlake Village, CA
- AI Therapeutics, Guilford, CT
- ALS Investment Fund, Amsterdam, Netherlands
- Alsonex, Brisbane, Australia
- Amgen, Thousand Oaks, CA
- Amylyx Pharmaceuticals Inc., Cambridge, MA
- Anida Pharma Inc., Cambridge, MA
- Annexon Biosciences, South San Francisco, CA
- Anida Pharma Inc., Cambridge, MA
- Arvinas, New Haven, CT
- AstraZeneca, London, UK
- Aquinnah Pharmaceuticals, Cambridge, MA
- Axxam SpA, Milan, Italy
- Biogen, Cambridge, MA
- Biohaven, New Haven, CT
- Boehringer-Ingelheim, Ingelheim am Rhein, Germany
- Bristol-Myers Squibb, New York City, NYClarus Ventures, Cambridge, MA
- Calico Biosciences, South San Francisco, CA
- Cassava Biosciences, Austin, TX
- Congenia, Milan, Italy
- CRISPR Therapeutics, Cambridge, MA
- Denali Therapeutics, Cambridge, MA
- Disarm Therapeutics, Cambridge, MA
- Eikonizo Therapeutics, Cambridge, MA
- Enclear Therapeutics, Newburyport, MA
- Expansion Therapeutics, Boston, MA
- F-Prime Capital Partners, Cambridge, MA
- Genentech, South San Francisco, CA
- Genzyme, Ridgefield, NJ
- GlaxoSmithKline, Clifton, NJ
- Inception Sciences, San Diego, CA
- Intellia Therapeutics, Cambridge, MA
- Insitro, South San Francisco, CA
- Ionis Pharmaceuticals, Carlsbad, CA
- Izumi Biosciences, Lexington, MA
- Karyopharm Therapeutics, MA
- Lundbeck, Valby, Denmark
- MeiraGTx, New York, NY
- Merck, Kenilworth, NJ
- miCure Therapeutics, Nes Ziona, Israel
- Mitsubishi Tanabe, Japan
- Neurimmune, Zurich, Switzerland
- Neuroscience Technologies,
- Nido Biosciences, Cambridge, MA
- Novartis, New York City, NY
- Novation Pharmaceuticals, Port Coquitlam, Canada
- ONO Pharmaceutical Co., LTD., Osaka, Japan
- OrbiMed Advisors LLC, New York, NY
- Ossianix, Philadelphia, PA
- Pfizer, Rye Brook, NY
- Prevail Therapeutics, New York, NY
- Prosetta Biosciences, Inc, San Francisco, CA
- Q Therapeutics, Salt Lake City, UT
- QurAlis Corporation, Cambridge, MA
- Regeneron, Tarrytown, NY
- Revalesio Corporation, Tacoma, WA
- Roche, Basel, Switzerland
- Regulus, San Diego, CA
- Sangamo Biosciences, Richmond, CA
- Shire, Lexington, MA
- Takeda, Osaka, Japan
- Teva, Petah Tikva, Israel
- Third Rock Ventures, Boston, MA
- United Neuroscience, Dublin, Ireland
- Verge Genomics, San Francisco, CA
- Vertex, Boston, MA
- Voyager Therapeutics, Cambridge, MA
- WAVE Life Sciences, Cambridge, MA
- Yumanity, Cambridge, MA
Foundations
We cannot do this alone. Our partners are critical to the success of the Innovation Ecosystem. Some of our key partners, today and over the past years, have been:
- American Academy of Neurology
- Answer ALS
- Association for Frontotemporal Degeneration
- ALS Association
- ALSFAC
- CReATe Consortium
- Matt’s Place Foundation
- Muscular Dystrophy Association
- National Institute of Neurological Disorders and Stroke
- New York Genome Center
- Northeast ALS Consortium
- Packard Center
- Prize4Life
- Project A.L.S.
